MRSN - Mersana Therapeutics

-

$undefined

N/A

(N/A)

Mersana Therapeutics NasdaqGS:MRSN Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana Biosciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Location: 840 Memorial Drive, Cambridge, MA, 02139, United States | Website: https://www.mersana.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-34.17M

Cash

102.3M

Avg Qtr Burn

-19.75M

Short % of Float

13.62%

Insider Ownership

1.48%

Institutional Own.

72.28%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Emiltatug Ledadotin (Emi-Le; XMT-1660) Details
Ovarian cancer, Breast cancer, Endometrial cancer

Phase 1

Data readout

XMT-2056 (HER2 ADC) Details
Solid tumor/s, Non-small cell lung carcinoma, Cancer

Phase 1

Data readout

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued

XMT-1592 (NaPi2b antigen) Details
Solid tumor/s, Non-small cell lung carcinoma, Cancer

Failed

Discontinued